Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon,ribavirin and sofosbuvir after a combined kidney–liver transplantation |
| |
| Authors: | Cyrielle Delabaudière Laurence Lavayssière Gaëlle Dörr Fabrice Muscari Marie Danjoux Federico Sallusto Jean Marie Peron Christophe Bureau Lionel Rostaing Jacques Izopet Nassim Kamar |
| |
| Affiliation: | 1. Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France;2. Department of Surgery and Liver Transplantation, University Hospital of Rangueil, Toulouse, France;3. Université Paul Sabatier, Toulouse, France;4. Department of Pathology, CHU Purpan, Toulouse, France;5. Department of Urology and Kidney Transplantation, CHU Rangueil, Toulouse, France;6. Department of Hepatology, Federation Digestive, CHU Purpan, Toulouse, France;7. INSERM U1043, IFR–BMT, CHU Purpan, Toulouse, France;8. Laboratory of Virology, CHU Purpan, Toulouse, France |
| |
| Abstract: | Fibrosing cholestatic hepatitis (FCH) is a classical but rare and severe form of recurrent hepatitis C virus (HCV) after liver transplantation. Classical anti‐HCV therapy, that is pegylated‐interferon (peg‐interferon) and ribavirin, has been shown to have limited efficacy in treating FCH. Herein, we report on the first case of successful use of peg‐interferon, ribavirin, plus sofosbuvir to treat HCV‐induced FCH in a combined liver–kidney transplant patient. Antiviral therapy was given for 24 weeks. HCV clearance occurred within 4 weeks after starting therapy and was maintained until 4 weeks after the end of therapy. Antiviral tolerance was good. We conclude that the use of sofosbuvir‐based anti‐HCV therapy can be successfully used to treat FCH after a liver or combined kidney–liver transplantation. |
| |
| Keywords: | fibrosing cholestatic hepatitis hepatitis C virus kidney transplantation liver transplantation sofosbuvir |
|
|
